The post Ethereum Eyes $8K-$10K After ATH Break appeared on BitcoinEthereumNews.com. Ethereum is close to breaking its all-time high, with price targets reachingThe post Ethereum Eyes $8K-$10K After ATH Break appeared on BitcoinEthereumNews.com. Ethereum is close to breaking its all-time high, with price targets reaching

Ethereum Eyes $8K-$10K After ATH Break

For feedback or concerns regarding this content, please contact us at [email protected]

Ethereum is close to breaking its all-time high, with price targets reaching $8K-$10K as momentum builds in 2026.

Ethereum is showing strong potential to break its all-time high (ATH) and reach new price levels. 

After years of consolidation, the cryptocurrency is now close to overcoming previous resistance points. 

This could trigger a significant price surge, potentially reaching the $8K-$10K range.

Ethereum Reclaims Key Price Levels

Ethereum has recently reclaimed critical price levels, signaling that it is entering a new phase of growth.

Over the past few years, the price ranged between $2,000 and $4,000, but Ethereum has now moved above those levels. This marks a significant step in regaining momentum after a period of volatility.

The price has been consistently testing resistance around $4,000, which now acts as a key threshold.

Ethereum’s ability to stay above this level for a sustained period may indicate strong support for further gains.

If the cryptocurrency maintains its current price structure, a breakout above the $4,800 ATH could become imminent.

Reaching new highs after reclaiming these levels would signal a strong bullish trend. Analysts are now eyeing the next resistance levels, with price projections moving higher.

The growing stability above these key levels suggests that Ethereum could soon test even higher targets.

Resistance Levels and Price Discovery

Breaking through Ethereum’s previous all-time high would trigger a price discovery phase, where new price targets are set.

Currently, the market is focused on Ethereum reaching and surpassing the $4,800 resistance level.

Once this level is cleared, Ethereum could experience a surge as there would be little resistance until it reaches the $6,000 range.

Price discovery phases often lead to rapid increases, especially if there is strong buying momentum.

Ethereum has previously demonstrated the ability to break past resistance levels, especially when market sentiment is bullish. If the price continues its upward trajectory, moving toward the $8,000-$10,000 range is not far-fetched.

Ethereum’s price movements beyond $4,800 will be critical in determining how high it can go.

A strong push through this level could set the stage for further gains, bringing new highs within reach.

As momentum builds, Ethereum could quickly surge towards its next major price targets.

Related Reading: Ethereum Supply Tightens as Whale Accumulation and Staking Offset Ongoing Sell Pressure

Market Sentiment and Institutional Interest

Market sentiment plays a major role in the success of any cryptocurrency, including Ethereum.

Positive sentiment has been building around Ethereum due to its growing use cases, especially in decentralized finance (DeFi).

Institutional interest in Ethereum has also been increasing, further supporting its price movement.

Ethereum’s transition to a more scalable network has made it an even more attractive asset for investors.

As adoption continues to grow in sectors like NFTs and DeFi, Ethereum’s long-term value proposition strengthens. This increased confidence in Ethereum’s future could drive it to new heights.

If Ethereum continues to gain institutional support and adoption, the $8,000-$10,000 range could be within reach.

The demand for Ethereum’s blockchain technology, combined with growing market enthusiasm, makes a strong bullish case for the cryptocurrency’s future.

With these factors at play, Ethereum’s upward trajectory may continue in the coming months.

Source: https://www.livebitcoinnews.com/ethereum-poised-for-strong-move-toward-8k-10k-after-ath-break/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09